Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Sees Large Increase in Short Interest

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was the recipient of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 2,570,000 shares, an increase of 16.8% from the February 13th total of 2,200,000 shares. Approximately 2.5% of the shares of the company are sold short. Based on an average trading volume of 916,800 shares, the short-interest ratio is presently 2.8 days.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Citigroup cut their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Piper Sandler reduced their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. BMO Capital Markets dropped their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. Finally, Bernstein Bank reduced their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of REGN. Principal Financial Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after purchasing an additional 2,828 shares during the last quarter. Intact Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $356,000. Golden State Equity Partners lifted its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% during the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock worth $967,000 after acquiring an additional 1,272 shares during the period. Fagan Associates Inc. boosted its position in shares of Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock worth $9,205,000 after acquiring an additional 3,832 shares during the last quarter. Finally, ABC Arbitrage SA acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $1,510,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $672.36 on Thursday. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The business has a fifty day moving average of $691.62 and a 200-day moving average of $822.93. The stock has a market cap of $73.51 billion, a price-to-earnings ratio of 17.56, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the company posted $11.86 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. As a group, analysts predict that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.